IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $719.55.
A number of equities research analysts have recently weighed in on the stock. BTIG Research dropped coverage on shares of IDEXX Laboratories in a research note on Friday, October 30th. They set a “buy” rating on the stock. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Barclays lowered their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. cut their price objective on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research report on Friday, October 16th.
Get Our Latest Research Report on IDXX
IDEXX Laboratories Price Performance
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.71 by $0.25. The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.22 earnings per share. As a group, equities research analysts forecast that IDEXX Laboratories will post 15.05 earnings per share for the current year.
Key IDEXX Laboratories News
Here are the key news stories impacting IDEXX Laboratories this week:
- Positive Sentiment: Morgan Stanley raised its price target on IDEXX, a potentially supportive analyst signal; the report provided here does not specify the new target. Morgan Stanley price target report
- Positive Sentiment: IDEXX’s Q3 results were described as best-in-class. The company reported EPS of $3.96, above the $3.71 consensus, and revenue of $1.21 billion, ahead of estimates and up 9.9% year over year. IDEXX Q3 results analysis
- Negative Sentiment: A Seeking Alpha article downgraded the stock, arguing that despite IDEXX’s strong business, its shares are too expensive. Valuation concerns may limit investor appetite. IDEXX valuation downgrade
- Negative Sentiment: Four directors and executives reported selling a combined 39,225 shares on November 4, worth about $27.4 million. Each reduced their reported holdings, a potential near-term sentiment headwind, though insider sales alone do not establish the reason for selling. Read More., Read More., Read More., Read More..
Insider Buying and Selling
In related news, Director Daniel M. Junius sold 1,200 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $704.07, for a total value of $844,884.00. Following the sale, the director directly owned 2,361 shares of the company’s stock, valued at $1,662,309.27. This represents a 33.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sharon E. Underberg sold 8,906 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $688.59, for a total value of $6,132,582.54. Following the completion of the transaction, the executive vice president owned 7,169 shares of the company’s stock, valued at approximately $4,936,501.71. This trade represents a 55.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 41,428 shares of company stock worth $28,567,934 over the last quarter. Company insiders own 0.79% of the company’s stock.
Institutional Trading of IDEXX Laboratories
A number of hedge funds have recently modified their holdings of the business. J.Safra Asset Management Corp bought a new position in shares of IDEXX Laboratories in the second quarter worth approximately $25,000. Elevation Wealth Partners LLC increased its stake in shares of IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after purchasing an additional 32 shares in the last quarter. Pension & Wealth Management Advisors Inc. bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $29,000. Arlington Trust Co LLC raised its position in shares of IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after purchasing an additional 19 shares during the period. Finally, Bell Investment Advisors Inc raised its position in shares of IDEXX Laboratories by 45.5% during the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock valued at $33,000 after purchasing an additional 20 shares during the period. Institutional investors own 87.84% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.
IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.
Featured Articles
- Five stocks we like better than IDEXX Laboratories
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
